blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2893350

EP2893350 - RESISTANCE BIOMARKERS FOR HDAC INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.07.2017
Database last updated on 14.09.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901 / US
[2015/29]
Inventor(s)01 / TROWE, Torsten, Bernhard
117 Tiffany Avenue
San Francisco, CA 94110 / US
 [2015/29]
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2015/29]
Application number, filing date13767166.506.09.2013
[2016/35]
WO2013US58379
Priority number, dateUS201261698341P07.09.2012         Original published format: US 201261698341 P
US201261726464P14.11.2012         Original published format: US 201261726464 P
US201361784501P14.03.2013         Original published format: US 201361784501 P
[2015/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014039744
Date:13.03.2014
Language:EN
[2014/11]
Type: A1 Application with search report 
No.:EP2893350
Date:15.07.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 13.03.2014 takes the place of the publication of the European patent application.
[2015/29]
Type: B1 Patent specification 
No.:EP2893350
Date:31.08.2016
Language:EN
[2016/35]
Search report(s)International search report - published on:EP13.03.2014
ClassificationIPC:G01N33/574, A61K38/15, G01N33/68
[2016/09]
CPC:
G01N33/574 (EP,CN,US); A61K38/12 (US); A61K38/15 (US);
A61K9/0019 (US); A61P35/00 (EP); A61P43/00 (EP);
G01N33/6893 (US) (-)
Former IPC [2015/29]G01N33/574
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/29]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:RESISTENZBIOMARKER FÜR HDAC-HEMMER[2015/29]
English:RESISTANCE BIOMARKERS FOR HDAC INHIBITORS[2015/29]
French:BIOMARQUEURS DE RÉSISTANCE AUX INHIBITEURS DE HDAC[2015/29]
Entry into regional phase27.03.2015National basic fee paid 
27.03.2015Designation fee(s) paid 
27.03.2015Examination fee paid 
Examination procedure27.03.2015Examination requested  [2015/29]
15.10.2015Amendment by applicant (claims and/or description)
16.03.2016Communication of intention to grant the patent
15.07.2016Fee for grant paid
15.07.2016Fee for publishing/printing paid
15.07.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.03.2016
Opposition(s)01.06.2017No opposition filed within time limit [2017/32]
Fees paidRenewal fee
28.09.2015Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.09.2013
AL31.08.2016
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IS31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
TR31.08.2016
IE06.09.2016
LU06.09.2016
MT30.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
[2018/46]
Former [2018/45]HU06.09.2013
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IS31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
TR31.08.2016
IE06.09.2016
LU06.09.2016
MT30.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2018/35]HU06.09.2013
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IS31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
IE06.09.2016
LU06.09.2016
MT30.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2018/33]HU06.09.2013
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IS31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
IE06.09.2016
LU06.09.2016
MT30.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2018/32]HU06.09.2013
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IS31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
IE06.09.2016
LU06.09.2016
MT30.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2018/30]HU06.09.2013
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IS31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
IE06.09.2016
LU06.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2017/40]AT31.08.2016
BE31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
IE06.09.2016
LU06.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2017/37]AT31.08.2016
BE31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
IE06.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2017/32]AT31.08.2016
BE31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SK31.08.2016
SM31.08.2016
IE06.09.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2017/23]AT31.08.2016
BE31.08.2016
CZ31.08.2016
DK31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
NL31.08.2016
PL31.08.2016
RO31.08.2016
RS31.08.2016
SE31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2017/13]AT31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
LT31.08.2016
LV31.08.2016
NL31.08.2016
RS31.08.2016
SE31.08.2016
BE30.09.2016
NO30.11.2016
GR01.12.2016
Former [2017/11]AT31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
LT31.08.2016
RS31.08.2016
SE31.08.2016
BE30.09.2016
NO30.11.2016
GR01.12.2016
Former [2017/10]FI31.08.2016
HR31.08.2016
LT31.08.2016
RS31.08.2016
SE31.08.2016
BE30.09.2016
NO30.11.2016
Former [2017/09]FI31.08.2016
LT31.08.2016
NO30.11.2016
Former [2017/07]LT31.08.2016
Cited inInternational search[A]WO2007067476  (MERCK & CO INC [US], et al) [A] 1-15 * the whole document * * abstract * * claims 4,16 *;
 [A]WO2008095050  (PHARMACYCLICS INC [US], et al) [A] 1-15 * the whole document * * abstract * * claims 1-5 *;
 [T]WO2013158984  (ACETYLON PHARMACEUTICALS INC [US]) [T] * the whole document * * page 12, line 24 - page 14, line 7 ** claim 16 *;
 [AD]  - STIMSON L ET AL, "Biomarkers for predicting clinical responses to HDAC inhibitors", CANCER LETTERS, NEW YORK, NY, US, vol. 280, no. 2, doi:10.1016/J.CANLET.2009.03.016, ISSN 0304-3835, (20090808), pages 177 - 183, (20090410), XP026146050 [AD] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.canlet.2009.03.016
by applicantUS4328245
 US4409239
 US4410545
 US4977138
 JPH0764872
 US6350458
 WO0220817
 WO2006129105
 US2009209616
 US7608280
 US7611724
 US2010093610
 WO2010047714
 US2012046442
    - FOTHERINGHAM ET AL., CANCER CELL, (2009), vol. 15, page 57
    - KHAN ET AL., PNAS, (2010), vol. 107, page 6532
    - SHAO ET AL., INT. J. CANCER, (2010), vol. 127, page 2199
    - BOLDEN ET AL., NATURE REVIEWS DRUG DISCOVERY, (2006), vol. 5, page 769
    - PEART ET AL., CANCER RESEARCH, (2003), vol. 63, page 4460
    - NEWBOLD ET AL., MOL. CANCER THER., (2008), vol. 7, page 1066
    - SCALA ET AL., MOLECULAR PHARMACOLOGY, (1997), vol. 51, page 1024
    - XIAO ET AL., J PHARMACOL AND EXP THER, (2005), vol. 313, page 268
    - BATES ET AL., BR JHAEMATOL, (2010), vol. 148, page 256
    - STIMSON ET AL., CANCER LETT, (2009), vol. 280, page 177
    - SASAKAWA ET AL., BIOCHEM PHARMACOL, (2005), vol. 69, page 603
    - PIEKARZ ET AL., BLOOD, (2004), vol. 103, page 4636
    - SANDOR ET AL., CLIN CANCER RES, (2002), vol. 8, page 718
    - MARSHALL ET AL., J EXP THER ONCOL, (2002), vol. 2, page 325
    - PIEKARZ ET AL., BLOOD, (2001), vol. 98, page 2865
    - PIEKARZ ET AL., J. CLINICAL ONCOLOGY, (2009), vol. 27, no. 32, page 5410
    - WHITTAKER ET AL., J CLIN ONCOL, (2010), vol. 28, pages 4485 - 4491
    - KIM ET AL., BIOCHERN AND BIOPHYS RES COMM, (2010), vol. 392, page 448
    - JUNG ET AL., LAB INVEST, (2008), vol. 88, page 153
    - KIM ET AL., CANCER RES, (2006), vol. 66, page 7490
    - EPPING ET AL., NATURE CELL BIOL, (2011), vol. 13, page 102
    - BRADNER ET AL., NAT CHEM BIOL, (2010), vol. 6, page 238
    - MANFRED E. WOLFF, Burger's Medicinal Chemistry and Drug Discovery, (1995), vol. 172-178, pages 949 - 982
    - GLOVER,, DNA Cloning, (1985), vol. I, II
    - Immunochemical Methods in Cell and Molecular Biology, ACADEMIC PRESS
    - WEIR AND BLACKWELL,, Handbook o.fExperimental Immunology, (1986), vol. I-IV
    - KAHN ET AL., J AM. CHEM. SOC., (1996), vol. 118, pages 7237 - 7238
    - NAKAJIMA ET AL., EXP CELL RES, (1998), vol. 241, pages 126 - 133
    - AEROS1L® 200, W.R. GRACE CO.
    - CAB-O-SIL®, CABOT CO.
    - CAB-O- SIL@, CABOT CO.
    - HAMBURGER AW; SALMON SE, "Primary bioassay of human tumor stem cells", SCIENCE, (1977), vol. 197, page 461
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.